Research Projects

In addition to devastation for the patients and their families, Alzheimer’s disease (AD) generates enormous costs for the wider European economy and is an urgent health priority. There are currently no drug treatments that can cure AD or other common forms of dementia. This absence of therapeutic interventions comes from a lack of understanding...

Alzheimer’s disease (AD) is the most common form of dementia in the Western World, representing an economic and social cost of billions of euros a year. Given the changing demographics of society, these costs will only increase over the coming decades.Amyloid plaques, composed of amyloid beta peptide (Abeta), are a defining characteristic of AD...

Alzheimer’s disease (AD) is the most common cause of dementia in the elderly, and a major reason for disability and death. The time course of AD varies between different people affected, and being able to tell in advance how the disease is likely to progress would have a great value for patient, their caregivers and for all of society. In the...

Raman HT is a company expert on Raman Spectroscopy (RS) which has developed a revolutionary medical device to diagnose Alzheimer’s Disease (AD) in blood plasma for the first time. Currently, there are only two accurate methods to diagnose AD, expensive, invasive with multiple side effects. Positron Emission Tomography (PET) scans the patient’s...

Everybody grows old. But while some people grow old in good health, others experience severe disease, such as Alzheimer's disease. Recent research demonstrates that Alzheimer's disease shares several features with the ageing process and suggests that the pathology is the consequence of something that goes wrong during physiological ageing...

Beta-amyloid (β-amyloid) deposition is considered to be a necessary - but not sufficient - step on the path towards Alzheimer’s disease (AD). Depiction of brain β-amyloid in vivo can support an early diagnosis, and even provide an opportunity for consider secondary prevention of AD. Currently, however, the value of β-amyloid PET remains elusive...

Alzheimer’s disease (AD) is an age-associated, irreversible neurodegenerative disorder. Α fundamental neuropathological hallmark of this disease is the accumulation of the amyloid-beta (Aβ) peptide in the extracellular space and its aggregation in the brain. Interestingly, critical role for a healthy brain is played by clearance mechanisms of...

In addition to impairments in episodic and spatial memory, a lack of awareness for one’s memory deficits (also referred to as anosognosia) may be considered a crucial cognitive marker of Alzheimer’s Disease (AD). However, although a growing body of interesting models have been proposed to explain this early symptom, what is still missing is a...

The study of protein aggregates and how they damage neuronal cells is important in order to understand the initiation and progression of several neurodegenerative diseases - including Alzheimer’s disease (AD), Parkinson’s disease (PD). The aggregation from the native monomeric proteins to beta sheet containing amyloid structures involves the...

Cognitive and mental disorders such as Dementia, Alzheimer´s, depression and Parkinson's disease, some of them closely related to ageing populations, have high social and economic burden. Nowadays, neurologists, psychiatrists, psychologists, gerontologists and general practitioners rely on subjective, time-consuming semi-structured interviews and...

As part of the Innovation policy of Andalusian Region, Fundación Descubre (www.fundaciondescubre.es) with the University of Almeria, University of Cordoba, University of Granada, University of Huelva, University of Malaga, Pablo de Olavide University, University of Seville, Jaen University and National Research Council (CSIC), the Association of...